AKT1 and neoplasm: Accordingly, immunotherapies that interfere with the PD-1/PD-L1 axis and activation of the PI3K/AKT/NF-κB pathway can restore immune dysfunction in tumors, which further emphasizes the role of the PD-1/PD-L1 axis in tumor pathogenesis.